Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Novelty in treatment of pulmonary fibrosis: pulmonary hypertension drugs and others.

Correale M, Totaro A, Lacedonia D, Montrone D, Di Biase M, Barbaro Foschino MP, Brunetti ND.

Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):169-78. Review.

PMID:
24011020
2.

Current and future treatment options in idiopathic pulmonary fibrosis.

Hauber HP, Blaukovitsch M.

Inflamm Allergy Drug Targets. 2010 Jul;9(3):158-72. Review.

PMID:
20518722
3.

Idiopathic pulmonary fibrosis: current and future treatment options.

Davies HR, Richeldi L.

Am J Respir Med. 2002;1(3):211-24. Review.

PMID:
14720059
4.

[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].

Montani D, Humbert M.

Rev Mal Respir. 2010 Feb;27(2):103-5. doi: 10.1016/j.rmr.2009.12.007. Epub 2010 Jan 25. French. No abstract available.

PMID:
20206056
5.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Shetty N, Derk CT.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. Review.

PMID:
21184655
6.

[Specific drugs for the treatment of pulmonary arterial hypertension - current status].

Stähler G.

Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S183-6. doi: 10.1055/s-0028-1091234. Epub 2008 Sep 23. Review. German.

PMID:
18814092
7.

Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.

Langleben D.

Clin Chest Med. 2007 Mar;28(1):117-25, viii. Review.

PMID:
17338931
8.

Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.

Fox B, Langleben D, Hirsch AM, Schlesinger RD, Eisenberg MJ, Joyal D, Blenkhorn F, Lesenko L.

Can J Cardiol. 2013 Jun;29(6):672-7. doi: 10.1016/j.cjca.2012.05.013. Epub 2012 Jul 21.

PMID:
22819360
9.

Immunomodulatory agents for idiopathic pulmonary fibrosis.

Davies HR, Richeldi L, Walters EH.

Cochrane Database Syst Rev. 2003;(3):CD003134. Review. Update in: Cochrane Database Syst Rev. 2010;(9):CD003134.

PMID:
12917947
10.

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Steiner MK, Preston IR.

Vasc Health Risk Manag. 2008;4(5):943-52. Review.

11.

Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.

Canestaro WJ, Forrester SH, Raghu G, Ho L, Devine BE.

Chest. 2016 Mar;149(3):756-66. doi: 10.1016/j.chest.2015.11.013. Epub 2016 Jan 13. Review.

PMID:
26836914
12.

[Pulmonary fibrosis--a therapeutic dilemma?].

Günther A, Markart P, Eickelberg O, Seeger W.

Med Klin (Munich). 2006 Apr 15;101(4):308-12. Review. German.

PMID:
16607487
13.
14.

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ.

Chest. 2009 Jan;135(1):122-9. doi: 10.1378/chest.08-1028. Epub 2008 Sep 23.

PMID:
18812445
15.

[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].

Hoeper MM.

Dtsch Med Wochenschr. 2006 Dec 8;131(49 Suppl 9):S308-10. Review. German.

PMID:
17139593
16.

Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.

Luo N, Ryan JJ.

Can J Cardiol. 2013 Jun;29(6):659-61. doi: 10.1016/j.cjca.2012.07.006. Epub 2012 Sep 15. No abstract available.

PMID:
22985784
17.

[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].

Cacoub P, Amoura Z, Langleben D.

Rev Med Interne. 2008 Apr;29(4):283-9. doi: 10.1016/j.revmed.2007.12.005. Epub 2008 Feb 19. Review. French.

PMID:
18243424
18.
19.

Effects of ambrisentan in a patient affected by combined pulmonary fibrosis and emphysema and by severe pulmonary hypertension: clinical, functional, and biomolecular findings.

Roccia F, Campolo B, Gallelli L, Spaccarotella C, Mongiardo A, Falcone D, Savino R, Pelaia G, Indolfi C, Maselli R.

Clin Drug Investig. 2013 Jun;33(6):451-7. doi: 10.1007/s40261-013-0083-z.

PMID:
23605508
20.

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

Opitz CF, Ewert R, Kirch W, Pittrow D.

Eur Heart J. 2008 Aug;29(16):1936-48. doi: 10.1093/eurheartj/ehn234. Epub 2008 Jun 17. Review.

Supplemental Content

Support Center